Photocure Initiates Enrolment Into Phase II Trial Of Cevira(R) For Cervical HPV Infection

Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, has initiated patient enrolment in the first trial to evaluate the optimal dose and safety of Cevira, a novel integrated intravaginal drug-delivery device. The study is a randomized, placebo controlled dose finding study in patients with low to moderate grade cervical intraepithelial neoplasia (CIN 1-2). The main end-point in the study is to assess the histological confirmed response of Cevira 3 months after treatment...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/IKj_9qfDJkQ/229006.php

auto sport medical rehab